We are live on ! Find out more
LUMO

Lumos Pharma, Inc. Common Stock

Delisted

LUMO was delisted on the 11th of December, 2024.

71 hedge funds and large institutions have $206M invested in Lumos Pharma, Inc. Common Stock in 2013 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 34 increasing their positions, 15 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

372% more call options, than puts

Call options by funds: $38.8M | Put options by funds: $8.22M

127% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 15

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

4% less capital invested

Capital invested by funds: $215M → $206M (-$8.71M)

4% less funds holding

Funds holding: 7471 (-3)

38% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 8

Holders
71
Holders Change
-3
Holders Change %
-4.05%
% of All Funds
2.3%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.06%
New
5
Increased
34
Reduced
15
Closed
8
Calls
$38.8M
Puts
$8.22M
Net Calls
+$30.6M
Net Calls Change
+$17.6M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$37.2M -$10.3M -63,946 -22%
RCM
2
RA Capital Management
Massachusetts
$34.6M
PC
3
PointState Capital
New York
$18.8M +$268K +1,667 +2%
First Eagle Investment Management
4
First Eagle Investment Management
New York
$14.6M +$2.45M +15,200 +21%
BFA
5
BlackRock Fund Advisors
California
$14.2M +$1.77M +11,018 +15%
TAM
6
Tiverton Asset Management
Delaware
$9.39M
Vanguard Group
7
Vanguard Group
Pennsylvania
$8.3M +$682K +4,235 +9%
Millennium Management
8
Millennium Management
New York
$7.35M +$5.36M +33,283 +326%
WSA
9
Wall Street Associates
California
$6.57M -$69.7K -433 -1%
Invesco
10
Invesco
Georgia
$5.33M +$113K +701 +2%
MCM
11
Montibus Capital Management
Oregon
$4.73M +$1.39M +8,611 +44%
State Street
12
State Street
Massachusetts
$4.68M +$215K +1,337 +5%
Barclays
13
Barclays
United Kingdom
$4.5M +$2.52M +15,648 +129%
Northern Trust
14
Northern Trust
Illinois
$4.45M +$333K +2,069 +9%
BIT
15
BlackRock Institutional Trust
California
$3.99M +$103K +642 +3%
SBH
16
Segall Bryant & Hamill
Illinois
$3.8M +$17.9K +111 +0.5%
Bank of New York Mellon
17
Bank of New York Mellon
New York
$1.48M +$38.5K +239 +3%
KCM
18
Knoll Capital Management
Florida
$1.45M +$536K +3,333 +63%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$1.37M +$48.9K +304 +4%
Principal Financial Group
20
Principal Financial Group
Iowa
$1.37M
Susquehanna International Group
21
Susquehanna International Group
Pennsylvania
$1.28M +$788K +4,898 +182%
TCIM
22
TIAA CREF Investment Management
New York
$1.27M +$8.69K +54 +0.7%
Deutsche Bank
23
Deutsche Bank
Germany
$1.04M -$275K -1,710 -22%
Morgan Stanley
24
Morgan Stanley
New York
$915K +$206K +1,282 +31%
BIM
25
BlackRock Investment Management
Delaware
$898K +$57.1K +355 +7%

LUMO Hedge Fund Activity: Q3 2013 in Review

71 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q3 2013, worth a combined $206M — down 4.1% from $215M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of LUMO and 5 opened new positions — a net loss of 3 holders — while 15 trimmed existing stakes and 34 added.

The largest buyer was Millennium Management, adding an estimated $5.36M. The largest seller was Fidelity Investments, cutting an estimated $10.3M.

  • 71 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q3 2013, down from 74 in Q2 2013.
  • Funds reported $206M of Lumos Pharma, Inc. Common Stock stock for Q3 2013, down 4.1% quarter-over-quarter.
  • 5 funds opened new Lumos Pharma, Inc. Common Stock positions in Q3 2013 and 8 closed out, a net change of -3 holders.
  • The largest Lumos Pharma, Inc. Common Stock buyer in Q3 2013 was Millennium Management, an estimated $5.36M added.
  • The largest Lumos Pharma, Inc. Common Stock seller in Q3 2013 was Fidelity Investments, an estimated $10.3M sold.

Based on aggregated 13F filings for Q3 2013.